{
  "attach_pages": "4",
  "attach_size": "786",
  "attach_type": "0",
  "attach_url": "https://pdf.dfcfw.com/pdf/H3_AP201808281183803115_1.pdf?1535464724000.pdf",
  "company_code": "10000296",
  "eitime": "2018-08-28 13:59:15",
  "extend": {},
  "info_code": "AP201808281183803115",
  "language": "0",
  "notice_date": "2018-08-28 00:00:00",
  "notice_title": "2018年半年报点评：内生稳健增长，研发费用和利息增长影响业绩",
  "page_size": 1,
  "page_size_ch": 0,
  "page_size_cht": 0,
  "page_size_en": 0,
  "rating": "A",
  "researcher": "朱国广",
  "security": [
    {
      "market_uni": "1",
      "publish_relation": [
        {
          "originalCode": "465",
          "publishName": "化学制药"
        }
      ],
      "short_name": "复星医药",
      "short_name_ch": "复星医药",
      "short_name_cht": "復星醫藥",
      "short_name_en": "FOSUN PHARMA",
      "stock": "600196"
    }
  ],
  "short_name": "复星医药",
  "source_sample_name": "西南证券",
  "star": "3"
}